Label Highlights CLARITIN Effectively Treats Indoor and Outdoor Allergies
KENILWORTH, N.J., Jan. 22 /PRNewswire-FirstCall/ -- Schering-Plough (NYSE: SGP) today announced that the U.S. Food and Drug Administration has approved additional labeling for CLARITIN(R) (loratadine), which clearly tells consumers that the non-drowsy over-the-counter medication relieves allergy symptoms caused by both indoor (also called perennial or year-round) and outdoor (also called seasonal) allergies.
"Schering-Plough is pleased that the FDA has approved the change to the CLARITIN label to help us to communicate to consumers that CLARITIN works hard to relieve both indoor and outdoor allergies," said John E. O'Mullane, BSc, PhD, Group Vice-President, Research and Development, Schering-Plough Consumer Health Care.
Common indoor allergens include mold, dust mites, and pet dander, while common outdoor allergens include grass, tree, and ragweed pollen. Though they stem from different sources, indoor and outdoor allergies have the same pathophysiology, meaning they affect the body in the same way. Symptoms of both types of allergies include runny nose; sneezing; itchy, watery eyes; and itching of the nose or throat.
"People often associate allergies with outdoor triggers like pollen and
grass, but many people's allergies are actually caused by things found in
their home, office, or school," said Marjorie Slankard, M.D., allergist and
clinical professor of medicine at the Columbia University College of
Physicians and Surgeons. "When choosing an allergy medication, it's
important to recognize that not all treatments are the same. Many patients
and providers prefer a non-drowsy antihistamine, such as CLARITIN, because
of its proven record in r
Copyright©2008 PR Newswire.
All rights reserved